Cardarine

Overview

GW-501516 ("Cardarine" is the gym name) was developed in the 1990s as a potential treatment for metabolic syndrome, dyslipidemia, and obesity. It increases endurance, improves lipid profiles, and increases fat oxidation by activating PPARδ — a nuclear receptor that regulates how cells use energy. Animal studies showed remarkable improvements in running endurance and fat metabolism, leading to early hype as an "exercise mimetic."

Development was halted in the mid-2000s when long-term carcinogenicity studies in rodents showed multiple cancer types at multiple dose levels. Short-duration Phase I and II clinical trials in healthy adults had been conducted before development ended. The compound was never approved for human use.

In athletic and bodybuilding communities, it's used for:

• Improving endurance (the "running compound")
• Cutting cycles (increased fat oxidation)

Mechanism

PPARδ is one of three PPAR receptor isoforms (alpha, gamma, delta). It's expressed throughout the body but particularly in muscle, where it regulates fatty acid metabolism, glucose uptake, and mitochondrial biogenesis.

Cardarine activates PPARδ, which causes:

• Increased fat oxidation in skeletal muscle
• Shifted muscle fiber composition toward more oxidative (endurance) fibers
• Improved insulin sensitivity
• Modulation of lipid metabolism (raising HDL, lowering LDL and triglycerides)
• Increased mitochondrial biogenesis (more mitochondria per cell)

It does NOT:

• Activate the androgen receptor
• Build muscle directly
• Affect testosterone production
• Aromatize
• Suppress the HPTA

The cancer concern (in detail)

This deserves its own section because it's the defining safety question and online discussion is unreliable.

What the studies actually showed: GSK conducted standard two-year carcinogenicity studies in rats and mice — the same studies required before any pharmaceutical can be approved for human use. In rats, Cardarine caused statistically significant increases in:

• Intestinal cancers (small and large intestine)
• Liver tumors (hepatocellular)
• Bladder/urothelial tumors
• Skin tumors
• Tongue/oral cancers
• Testicular tumors (in males)
• Endometrial cancers (in females)

These occurred at multiple dose levels, in both sexes, across the dose range studied — not just at extreme doses.

The "doses were absurdly high" claim: A common online defense is that the doses used in the rat studies were "wildly higher than what humans take." This is partially true but misleading:

• Interspecies scaling from a rodent exposure to a human one is an approximation, so "far higher than anything a person takes" is not a settled comparison
• Cancer was seen even at the lower amounts tested, suggesting the cancer signal wasn't only a high-exposure phenomenon
• Long-term human exposure studies were never conducted because the rat findings ended development

What we don't know:

• Whether the rat carcinogenicity translates directly to humans (sometimes it does, sometimes it doesn't)
• What constitutes a "safe" duration or dose in humans
• Whether cancer risk is additive across multiple cycles
• Long-term human outcomes (we simply don't have decades of data)

What we do know:

• WADA bans it specifically with reference to the cancer findings
• Pharmaceutical regulators (FDA, EMA) have never approved it for any use
• Mechanism-of-action studies suggest the cancer effect may be related to PPARδ's role in cell proliferation pathways, which is biologically plausible

The honest takeaway: This is a compound where the manufacturer studied long-term safety and stopped development because of what they found. That's an unusual situation in the research-chemical world — most SARMs were never long-term safety tested at all. With Cardarine, the data exists and the answer was "not safe enough to develop."

Pharmacokinetics

• Half-life: ~20-24 hours (some sources cite shorter)
• Tmax (oral): 1-2 hours
• Bioavailability (oral): good
• Metabolism: hepatic
• Elimination: urinary

Expected effects

• Significant endurance improvements (often noticeable within 1-2 weeks)
• Improved fat oxidation during cardio
• Better cardio recovery between sessions
• Improved lipid panel (HDL up, LDL and triglycerides down) — typically meaningful even in non-AAS users
• Mild fat loss assistance during caloric deficit
• No direct muscle gain
• No water retention, no hardening effect

Side effect profile

Aside from the carcinogenicity concern:

• HPTA suppression: None. Doesn't affect testosterone.
• Lipid changes: HDL increases, LDL and triglycerides decrease.
• Liver: Mild stress possible but not in the same category as oral AAS or YK-11.
• Estradiol: No effect.
• Generally well-tolerated short-term: Users report few acute side effects, which is part of why it's appealing — and part of why the long-term cancer concern gets dismissed.

Bloodwork monitoring

Markers to monitor before and after cycles. The lipid changes are measurable and documented in user bloodwork:

• Full lipid panel (HDL, LDL, total cholesterol, triglycerides)
• ALT, AST (general liver monitoring)
• CBC (general health)
• Glucose, HbA1c (metabolic effect monitoring)

There is no routine test for the cancer concern — that's a long-term risk that doesn't show up in standard bloodwork. Worth noting because some users assume "my bloodwork is fine, so Cardarine must be safe."

Relevant markers

• hdl
• ldl
• total_cholesterol
• triglycerides
• apob
• alt
• ast
• ggt
• fasting_glucose
• hba1c
• fasting_insulin

Pharmacokinetic modeling parameters

ka: 1.5 /day
ke: 0.69 /day
Vd: 70 L
F: 0.85
half_life_hours: 24

Notes and caveats

• The single most important safety conversation in the SARM/PED space. Most users either dismiss the cancer concern entirely or are paralyzed by it. The truthful position is in between: real animal data showed multiple cancers at multiple doses, human long-term data does not exist, and individual users are making a personal risk assessment with incomplete information.

• No long-term human safety data exists, and no duration or level of human exposure is known to be safe. The rodent cancer findings came from long-term continuous exposure.

• WADA bans Cardarine specifically with a cancer warning in their prohibited substances documentation — relatively rare for them to do.

• Heavily counterfeited. Cardarine is one of the most commonly faked compounds in the research-chemical market. Independent testing has found products labeled as Cardarine containing anything from underdose to wrong actives to nothing at all.

• The endurance and lipid effects are what the compound was developed and is taken for, and the carcinogenicity findings in the two-year rodent studies are why development stopped. Both come from the same development record, and long-term human data covers neither.